PCVX Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of -- compared to Vaxcyte, Inc.'s net margin of 18.15%. Vaxcyte, Inc.'s return on equity of -25.29% beat Merck & Co., Inc.'s return on equity of 36.76%.

Vaxcyte, Inc. has a consensus price target of $109.00, signalling upside risk potential of 82.21%. On the other hand Merck & Co., Inc. has an analysts' consensus of $127.46 which suggests that it could grow by 6.37%. Given that Vaxcyte, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Vaxcyte, Inc. is more attractive than Merck & Co., Inc..

Vaxcyte, Inc. has a beta of 1.312, which suggesting that the stock is 31.221% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.269, suggesting its less volatile than the S&P 500 by 73.077%.

Vaxcyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.85 per share. Vaxcyte, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vaxcyte, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Vaxcyte, Inc.'s net income of -$246.5M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Vaxcyte, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte, Inc. is -- versus 4.63x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -- compared to Vaxcyte, Inc.'s net margin of -121.83%. Vaxcyte, Inc.'s return on equity of -25.29% beat Moderna, Inc.'s return on equity of -29.19%.

Vaxcyte, Inc. has a consensus price target of $109.00, signalling upside risk potential of 82.21%. On the other hand Moderna, Inc. has an analysts' consensus of $42.25 which suggests that it could fall by -15.21%. Given that Vaxcyte, Inc. has higher upside potential than Moderna, Inc., analysts believe Vaxcyte, Inc. is more attractive than Moderna, Inc..

Vaxcyte, Inc. has a beta of 1.312, which suggesting that the stock is 31.221% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.087%.

Vaxcyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Vaxcyte, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $678M. Vaxcyte, Inc.'s net income of -$246.5M is higher than Moderna, Inc.'s net income of -$826M. Notably, Vaxcyte, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte, Inc. is -- versus 9.97x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -- compared to Vaxcyte, Inc.'s net margin of 11.91%. Vaxcyte, Inc.'s return on equity of -25.29% beat Novavax, Inc.'s return on equity of --.

Vaxcyte, Inc. has a consensus price target of $109.00, signalling upside risk potential of 82.21%. On the other hand Novavax, Inc. has an analysts' consensus of $13.78 which suggests that it could grow by 45.18%. Given that Vaxcyte, Inc. has higher upside potential than Novavax, Inc., analysts believe Vaxcyte, Inc. is more attractive than Novavax, Inc..

Vaxcyte, Inc. has a beta of 1.312, which suggesting that the stock is 31.221% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.544, suggesting its more volatile than the S&P 500 by 154.382%.

Vaxcyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

Vaxcyte, Inc. quarterly revenues are --, which are smaller than Novavax, Inc. quarterly revenues of $147.1M. Vaxcyte, Inc.'s net income of -$246.5M is lower than Novavax, Inc.'s net income of $17.5M. Notably, Vaxcyte, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 3.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte, Inc. is -- versus 1.44x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Vaxcyte, Inc.'s net margin of -9.34%. Vaxcyte, Inc.'s return on equity of -25.29% beat Pfizer Inc.'s return on equity of 8.69%.

Vaxcyte, Inc. has a consensus price target of $109.00, signalling upside risk potential of 82.21%. On the other hand Pfizer Inc. has an analysts' consensus of $28.43 which suggests that it could grow by 6.94%. Given that Vaxcyte, Inc. has higher upside potential than Pfizer Inc., analysts believe Vaxcyte, Inc. is more attractive than Pfizer Inc..

Vaxcyte, Inc. has a beta of 1.312, which suggesting that the stock is 31.221% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.474, suggesting its less volatile than the S&P 500 by 52.65%.

Vaxcyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.47% to investors and pays a quarterly dividend of $0.43 per share. Vaxcyte, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.

Vaxcyte, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Vaxcyte, Inc.'s net income of -$246.5M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Vaxcyte, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 19.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte, Inc. is -- versus 2.42x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.